Generic Nuzyra Availability
Last updated on Apr 10, 2025.
Nuzyra is a brand name of omadacycline, approved by the FDA in the following formulation(s):
NUZYRA (omadacycline tosylate - powder;intravenous)
-
Manufacturer: PARATEK PHARMS INC
Approval date: October 2, 2018
Strength(s): EQ 100MG BASE/VIAL [RLD]
NUZYRA (omadacycline tosylate - tablet;oral)
-
Manufacturer: PARATEK PHARMS INC
Approval date: October 2, 2018
Strength(s): EQ 150MG BASE [RLD]
Is there a generic version of Nuzyra available?
No. There is currently no therapeutically equivalent version of Nuzyra available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Nuzyra. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
9-aminomethyl minocycline compounds and uses thereof
Patent 10,111,890
Issued: October 30, 2018
Inventor(s): Tanaka S. Ken & Tzanis Evangelos L. & Garrity-Ryan Lynne & Manley Amy L.
Assignee(s): Paratek Pharmaceuticals, Inc.Methods and compositions for using a tetracycline compound to treat bacterial infections are described. In one embodiment, for example, the invention provides a method of treating a subject for an infection, comprising administering to said subject an effective amount of 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, such that said subject is treated, wherein the 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline is administered orally at a dose of about 450 mg per day for two consecutive days, then at a dose of about 300 mg per day for 5 or more days.
Patent expiration dates:
- August 3, 2037✓
- August 3, 2037
-
Minocycline compounds and methods of use thereof
Patent 10,124,014
Issued: November 13, 2018
Inventor(s): Johnston Sean M. & Arbeit Robert D. & Bigger Thomas J. & Molnar Dennis P. & Tanaka S. Ken
Assignee(s): Paratek Pharmaceuticals, Inc.Methods and compositions for using a tetracycline compound to treat bacterial infections are described. In one embodiment, for example, the invention provides a method of treating a subject for an infection, comprising administering to said subject an effective amount of 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, such that said subject is treated, wherein said infection is selected from the group consisting of MSSA, MRSA, -, or combinations thereof.
Patent expiration dates:
- March 5, 2029✓
- March 5, 2029
-
9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP)
Patent 10,383,884
Issued: August 20, 2019
Inventor(s): Tzanis Evangelos L. & McGovern Paul & Manley Amy L. & Garrity-Ryan Lynne & Tanaka S. Ken
Assignee(s): Paratek Pharmaceuticals, Inc.The invention disclosed herein provides a method for treating Community-Acquired Bacterial Pneumonia (CABP) using 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, in either oral or IV doses or a combination of both.
Patent expiration dates:
- October 31, 2037✓
- October 31, 2037
-
9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP)
Patent 10,835,542
Issued: November 17, 2020
Inventor(s): Tzanis Evangelos L. & McGovern Paul & Manley Amy L. & Garrity-Ryan Lynne & Tanaka S. Ken
Assignee(s): Paratek Pharmaceuticals, Inc.The invention disclosed herein provides a method for treating Community-Acquired Bacterial Pneumonia (CABP) using 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, in either oral or IV doses or a combination of both.
Patent expiration dates:
- October 31, 2037✓
- October 31, 2037
-
9-aminomethyl substituted minocycline compounds
Patent 7,553,828
Issued: June 30, 2009
Inventor(s): Nelson; Mark L. et al.
Assignee(s): Paratek Pharmaceuticals, Inc. (Boston, MA)The present invention pertains, at least in part, to novel 9-substituted minocycline compounds. These minocycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and minocycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.
Patent expiration dates:
- June 2, 2025✓
- June 2, 2025
-
Salts and polymorphs of 9-(2,2-dimethylpropyl-aminomethyl) minocycline
Patent 8,383,610
Issued: February 26, 2013
Inventor(s): Cvetovich Raymond & Warchol Tadeusz
Assignee(s): Paratek Pharmaceuticals, Inc.Crystalline forms, including salts and polymorphs, of a compound useful in the treatment of tetracycline compound-responsive states are provided herein. The crystalline compounds are useful for the treatment or prevention of conditions and disorders such as bacterial infections and neoplasms, as well as other known applications for tetracycline compounds in general.
Patent expiration dates:
- September 23, 2030✓
- September 23, 2030
-
Minocycline compounds and methods of use thereof
Patent 9,265,740
Issued: February 23, 2016
Inventor(s): Johnston Sean M. & Arbeit Robert D. & Bigger Thomas J. & Molnar Dennis P. & Tanaka S. Ken
Assignee(s): Paratek Pharmaceuticals, Inc.-124418Methods and compositions for using a tetracycline compound to treat bacterial infections are described. In one embodiment, for example, the invention provides a method of treating a subject for an infection, comprising administering to said subject an effective amount of 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, such that said subject is treated, wherein said infection is selected from the group consisting of MSSA, MRSA, -, or combinations thereof.
Patent expiration dates:
- October 24, 2030✓
- October 24, 2030✓✓
- October 24, 2030
-
Oral and injectable formulations of tetracycline compounds
Patent 9,314,475
Issued: April 19, 2016
Inventor(s): Johnston Sean
Assignee(s): Paratek Pharmaceuticals, Inc.Injectable and oral formulations of a tetracycline compound are described. In one embodiment, the invention pertains to an oral formulation of a 9-aminomethyl tetracycline compound, or a salt thereof, in tablet form or capsule. The formulations may be used, for example, to treat infections.
Patent expiration dates:
- March 18, 2031✓
- March 18, 2031
-
Minocycline compounds and methods of use thereof
Patent 9,724,358
Issued: August 8, 2017
Inventor(s): Johnston Sean M. & Arbeit Robert D. & Bigger Thomas J. & Molnar Dennis P. & Tanaka S. Ken
Assignee(s): Paratek Pharmaceuticals, Inc.Methods and compositions for using a tetracycline compound to treat bacterial infections are described. In one embodiment, for example, the invention provides a method of treating a subject for an infection, comprising administering to said subject an effective amount of 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, such that said subject is treated, wherein said infection is selected from the group consisting of MSSA, MRSA, -, Viridans , or combinations thereof.
Patent expiration dates:
- March 5, 2029✓
- March 5, 2029
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- October 2, 2023 - NEW CHEMICAL ENTITY
- October 2, 2028 - GENERATING ANTIBIOTIC INCENTIVES NOW
More about Nuzyra (omadacycline)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: tetracyclines
- Breastfeeding
- En español
Patient resources
- Nuzyra oral/injection drug information
- Nuzyra (Omadacycline Intravenous) (Advanced Reading)
- Nuzyra (Omadacycline Oral) (Advanced Reading)
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
